Close

AbbVie (ABBV) Announces FDA Approval for Addition of Moderate to Severe Fingernail Psoriasis Data to HUMIRA Prescribing Information

March 30, 2017 7:04 AM EDT Send to a Friend
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login